Sign Out
ROBOL has been used successfully to produce regression in neoplastic conditions such as: acute leukaemia, Wilms' tumour, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, lymphomas of both Hodgkin's and non-Hodgkin's type, bronchogenic (lung) carcinoma, thyroid carcinoma, hepatomas, ovarian carcinoma, etc. Doxorubicin is also indicated by intravesical administration in the primary management of non-metastatic carcinoma of the bladder (Tis, T1, T2).
Doxorubicin has some antitumour activities against stomach, cervix, head and neck, testicle, myeloma and endometrial cancer.
